ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Leonidas Platanias named director of Lurie Comprehensive Cancer Center

October 3, 2014

Broad Institute wins NIH grant for first national SNP genotyping center.

October 8, 2004

Women’s Health Trial RFPs Issued; Three Clinical Centers Sought

April 12, 1991

FDA Revises Package Insert, Seeks To Limit Product Liability Suits In State Courts.

January 20, 2006

Leukemia & Lymphoma Society offers translational research grants.

October 24, 2003

Controversial Toxicology Protocol Is “Getting The Information We Need;” Additionally Revision Made

March 2, 1984